TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 7282427

Group type: EXPERIMENTAL
Intervention: ceruletide 0.3 microgram/kg intramuscularly
Number of subjects: 148

Group type: EXPERIMENTAL
Intervention: ceruletide 0.03 microgram/kg intravenously
Number of subjects: 148

Group type: EXPERIMENTAL
Intervention: ceruletide 0.05 microgram/kg intravenously
Number of subjects: 148

Group type: COMPARATOR
Intervention: cholecystokinin
Number of subjects: 148
Study: 31665842

Group type: EXPERIMENTAL
Intervention: Five-in-one asthma management model (standardized asthma treatment, asthma diary, PEF monitoring, reasonable diet and physical exercise)
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: Five-in-one asthma management model
Number of subjects: 59

Group type: COMPARATOR
Intervention: Routine medication and regular outpatient consultation (control group)
Number of subjects: 59
Study: 27855493

Group type: EXPERIMENTAL
Intervention: Muscle-damaging exercise performed during visit 3
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control group (no muscle-damaging exercise)
Number of subjects: 20
Study: 25420010

Group type: EXPERIMENTAL
Intervention: Manual therapy and exercise program aimed at increasing the size of the intervertebral foramen (IVF) of the affected nerve root
Number of subjects: 36

Group type: COMPARATOR
Intervention: Manual therapy and exercise program without the specific goal of increasing the size of the IVF
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Manual therapy and exercise program aimed at increasing the size of the IVF of the affected nerve root
Number of subjects: 36
Study: 23831221

Group type: EXPERIMENTAL
Intervention: K-115 0.1%
Number of subjects: 210

Group type: EXPERIMENTAL
Intervention: K-115 0.2%
Number of subjects: 210

Group type: EXPERIMENTAL
Intervention: K-115 0.4%
Number of subjects: 210

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 210
Study: 21505984

Group type: EXPERIMENTAL
Intervention: Intensive insulin therapy (conventional therapy plus continuous insulin pumping to control blood glucose at 4.4‐6.1 mmol/L)
Number of subjects: 114

Group type: COMPARATOR
Intervention: Conventional therapy (control group)
Number of subjects: 114
Study: 19409038

Group type: EXPERIMENTAL
Intervention: Vandetanib + Docetaxel/Prednisolone (DP)
Number of subjects: 86

Group type: COMPARATOR
Intervention: Placebo + Docetaxel/Prednisolone (DP)
Number of subjects: 86
Study: 17584491

Group type: EXPERIMENTAL
Intervention: Intrapartum/neonatal nevirapine added to antiretroviral prophylaxis
Number of subjects: 1350

Group type: EXPERIMENTAL
Intervention: Highly active antiretroviral therapy (HAART)
Number of subjects: 1350

Group type: EXPERIMENTAL
Intervention: Elective caesarean delivery
Number of subjects: 1350

Group type: EXPERIMENTAL
Intervention: HIV RNA levels <400 copies/ml at delivery
Number of subjects: 1350

Group type: EXPERIMENTAL
Intervention: Symptoms of HIV infection
Number of subjects: 1350
Study: 15121722

Group type: EXPERIMENTAL
Intervention: Ultrasound-guided central venous catheterization
Number of subjects: 124

Group type: COMPARATOR
Intervention: Traditional landmark-guided central venous catheterization
Number of subjects: 124
Study: 11471097

Group type: EXPERIMENTAL
Intervention: Ribavirin monotherapy for an additional 6 months
Number of subjects: 46

Group type: COMPARATOR
Intervention: Stopped use of both IFN and ribavirin
Number of subjects: 46
Study: 11103847

Group type: EXPERIMENTAL
Intervention: Diet and exercise training (weight loss, aerobic and resistive exercise)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Aerobic exercise training
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Resistive training
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Lifestyle modifications (bodyweight loss and physical activity)
Number of subjects: 0
Study: 9120160

Group type: EXPERIMENTAL
Intervention: Carvedilol
Number of subjects: 123

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 123
Study: 8241852

Group type: EXPERIMENTAL
Intervention: Arthroscopic surgery
Number of subjects: 125

Group type: EXPERIMENTAL
Intervention: Supervised exercise regimen
Number of subjects: 125

Group type: COMPARATOR
Intervention: Placebo soft laser treatment
Number of subjects: 125
Study: 2863843

Group type: EXPERIMENTAL
Intervention: Lorazepam
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Alprazolam
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Diazepam
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study: 31002955

Group type: EXPERIMENTAL
Intervention: PALS intervention (6-month structured diet and exercise program)
Number of subjects: 200

Group type: COMPARATOR
Intervention: Control (general diet and physical activity guidelines delivered in a single session)
Number of subjects: 200
Study: 29894762

Group type: EXPERIMENTAL
Intervention: High Energy Dinner (HED)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Low Energy Dinner (LED)
Number of subjects: 24
Study: 26846185

Group type: EXPERIMENTAL
Intervention: Deep brain stimulation (DBS) surgery
Number of subjects: 0

Group type: COMPARATOR
Intervention: Best medical therapy
Number of subjects: 0
Study: 24503231

Group type: EXPERIMENTAL
Intervention: Buddy strapping of the injured finger to its neighbor noninjured finger for a week
Number of subjects: 121

Group type: COMPARATOR
Intervention: Aluminum extension blocking orthosis for a week in 15° flexion
Number of subjects: 121
Study: 21741060

Group type: EXPERIMENTAL
Intervention: IGFBP-1 levels in T2DM subjects (21.7 ± 3.5 ng/mL)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: IGFBP-1 levels in NGT subjects with insulin resistance (25.5 ± 6.5 ng/mL)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Insulin resistance association with IGFBP-1
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Type 2 diabetes mellitus association with IGFBP-1
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: IGFBP-1 levels with increasing number of metabolic abnormalities
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: IGFBP-1 association with metabolic syndrome
Number of subjects: 100
Study: 20923385

Group type: EXPERIMENTAL
Intervention: Levalbuterol plus ipratropium
Number of subjects: 141

Group type: COMPARATOR
Intervention: Levalbuterol alone
Number of subjects: 141
Study: 18546895

Group type: EXPERIMENTAL
Intervention: Propofol target concentration of 1.5 microg x ml(‐1)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Propofol target concentration of 2.0 microg x ml(‐1)
Number of subjects: 30
Study: 16060935

Group type: EXPERIMENTAL
Intervention: Treatment in a stroke unit (SU)
Number of subjects: 484

Group type: COMPARATOR
Intervention: Treatment in a general medical ward (GMW)
Number of subjects: 484

Group type: EXPERIMENTAL
Intervention: Scandinavian Stroke Scale (SSS) score < 30 on admission
Number of subjects: 484

Group type: EXPERIMENTAL
Intervention: Overall prevalence of PSE
Number of subjects: 484
Study: 12768797

Group type: COMPARATOR
Intervention: Not specified
Number of subjects: 81
Study: 10433097

Group type: EXPERIMENTAL
Intervention: CM cells cultured in high glucose (11 mM)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: CM cells cultured in low glucose (0.8 mM)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Control subjects (27 age-matched)
Number of subjects: 32
Study: 7674439

Group type: EXPERIMENTAL
Intervention: Small-movement therapy
Number of subjects: 10

Group type: COMPARATOR
Intervention: Standard therapy
Number of subjects: 10
Study: 2116773

Group type: EXPERIMENTAL
Intervention: Monthly intravenous methylprednisolone pulsing (steroid group)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo (placebo group)
Number of subjects: 40
Study: 31101627

Group type: EXPERIMENTAL
Intervention: Rituximab plus lenalidomide (15 mg orally daily for 18 weeks)
Number of subjects: 154

Group type: COMPARATOR
Intervention: Rituximab (375 mg/m2 IV on day 1 of weeks 1‐4 and repeated during weeks 12‐15 in responding patients)
Number of subjects: 154

Group type: EXPERIMENTAL
Intervention: Rituximab plus lenalidomide
Number of subjects: 154

Group type: COMPARATOR
Intervention: Rituximab
Number of subjects: 154
Study: 29183037

Group type: EXPERIMENTAL
Intervention: Wiping plus oral nutritional supplements (ONS)
Number of subjects: 252

Group type: COMPARATOR
Intervention: Conventional oral care (Control)
Number of subjects: 252
Study: 25584004

Group type: EXPERIMENTAL
Intervention: Docetaxel 20 mg/m2 plus cisplatin 25 mg/m2 on days 1, 8, and 15, every 4 weeks
Number of subjects: 276

Group type: COMPARATOR
Intervention: Docetaxel 60 mg/m2 on day 1, every 3 weeks
Number of subjects: 276
Study: 23596781

Group type: EXPERIMENTAL
Intervention: Modified Shuyu Pill (MSP)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Donepezil hydrochloride
Number of subjects: 100
Study: 21253706

Group type: EXPERIMENTAL
Intervention: Zolpidem (single dose for the first seven post-operative nights)
Number of subjects: 29

Group type: COMPARATOR
Intervention: Placebo (gelatin capsule similar in appearance to zolpidem)
Number of subjects: 29
Study: 19731779

Group type: EXPERIMENTAL
Intervention: Integrative relaxation training (IRT) - 12 weekly group sessions
Number of subjects: 32

Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 32
Study: 18257345

Group type: EXPERIMENTAL
Intervention: Electrical plum-blossom needle therapy
Number of subjects: 160

Group type: COMPARATOR
Intervention: Tropicamide eye drops (Control)
Number of subjects: 160
Study: 14724106

Group type: EXPERIMENTAL
Intervention: Parnaparin (0.4 ml subcutaneously every 12 h for 7 days 12 h after thrombolysis, n=96)
Number of subjects: 186

Group type: COMPARATOR
Intervention: Unfractionated heparin (100 U/kg x b.w. intravenous bolus, 1,000 U/h continuous infusion for 3 days, then subcutaneous 7500 U every 12 h for 4 days, n=90)
Number of subjects: 186

Group type: EXPERIMENTAL
Intervention: Parnaparin
Number of subjects: 186

Group type: COMPARATOR
Intervention: Unfractionated heparin
Number of subjects: 186
Study: 11759189

Group type: EXPERIMENTAL
Intervention: Oral montelukast (n = 83)
Number of subjects: 124

Group type: COMPARATOR
Intervention: Inhaled beclomethasone 100 mcg three times daily (n = 41)
Number of subjects: 124

Group type: EXPERIMENTAL
Intervention: Oral montelukast
Number of subjects: 124

Group type: COMPARATOR
Intervention: Inhaled beclomethasone
Number of subjects: 124

Group type: EXPERIMENTAL
Intervention: Both treatments
Number of subjects: 124
Study: 9462573

Group type: EXPERIMENTAL
Intervention: Early invasive strategy (routine coronary angiography followed by myocardial revascularization if feasible)
Number of subjects: 920

Group type: COMPARATOR
Intervention: Early conservative strategy (noninvasive predischarge stress testing with planar thallium scintigraphy and radionuclide ventriculography)
Number of subjects: 920
Study: 7992095

Group type: EXPERIMENTAL
Intervention: Interferon‐alfa (IFN‐alpha)
Number of subjects: 0
Study: 3377519

Group type: EXPERIMENTAL
Intervention: Transparent film dressing (TFD [Bioclusive])
Number of subjects: 58

Group type: COMPARATOR
Intervention: Conventional dry gauze dressing (Curity) and antibiotic ointment (Polysporin)
Number of subjects: 58
Study: 31538948

Group type: EXPERIMENTAL
Intervention: TECCU (G_TECCU intervention group)
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: G_NT (nurse‐assisted telephone care)
Number of subjects: 63

Group type: COMPARATOR
Intervention: G_control (standard care)
Number of subjects: 63
Study: 29145813

Group type: EXPERIMENTAL
Intervention: Gist version of decision aid
Number of subjects: 1031

Group type: COMPARATOR
Intervention: Extended version of decision aid
Number of subjects: 1031
Study: 26342782

Group type: EXPERIMENTAL
Intervention: Ondansetron 4 mg
Number of subjects: 80

Group type: COMPARATOR
Intervention: Saline (control)
Number of subjects: 80
Study: 23280675

Group type: EXPERIMENTAL
Intervention: Remotiv® (Hypericum perforatum Special Extract - Ze 117)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Nicabate CQ Nicotine Replacement therapy (NRT)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Combined NRT/HP
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: HP group
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: NRT group
Number of subjects: 20
Study: 21593301

Group type: EXPERIMENTAL
Intervention: Insulin targeting postprandial glycemia
Number of subjects: 1115

Group type: COMPARATOR
Intervention: Insulin targeting fasting/premeal glycemia
Number of subjects: 1115
Study: 18283509

Group type: EXPERIMENTAL
Intervention: Er:YAG laser treatment (2,940 nm) with variable pulse durations (1 ms to 2 ms) and energy densities (800 mJ/cm(2) to 1,400 mJ/cm(2)), 4 to 8 passes, single session
Number of subjects: 30
Study: 16488800

Group type: EXPERIMENTAL
Intervention: Facilitated PCI with full-dose tenecteplase (n=829)
Number of subjects: 1667

Group type: COMPARATOR
Intervention: Standard PCI (n=838)
Number of subjects: 1667

Group type: EXPERIMENTAL
Intervention: Facilitated PCI with full-dose tenecteplase
Number of subjects: 1667

Group type: COMPARATOR
Intervention: Standard PCI
Number of subjects: 1667
Study: 14504416

Group type: EXPERIMENTAL
Intervention: Gabapentin (300 mg initial dose, mean dosage 800 +/- 397 mg, range 300-1200 mg)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Ropinirole (0.5 mg initial dose, mean dosage 0.78 +/- 0.47 mg, range 0.25-1.50 mg)
Number of subjects: 16
Study: 10881481

Group type: EXPERIMENTAL
Intervention: Thoracoscopic lung biopsy
Number of subjects: 61

Group type: COMPARATOR
Intervention: Open lung biopsy
Number of subjects: 61
Study: 9165958

Group type: EXPERIMENTAL
Intervention: Midazolam 0.5 mg.kg‐1 given 30 min pre-operatively
Number of subjects: 85

Group type: COMPARATOR
Intervention: Trimeprazine 2 mg.kg‐1 given 90 min pre-operatively
Number of subjects: 85

Group type: COMPARATOR
Intervention: Placebo preparation
Number of subjects: 85

Group type: EXPERIMENTAL
Intervention: Midazolam
Number of subjects: 85

Group type: COMPARATOR
Intervention: Trimeprazine
Number of subjects: 85

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 85

Group type: COMPARATOR
Intervention: Midazolam, Trimeprazine, Placebo
Number of subjects: 85
Study: 8238827

Group type: EXPERIMENTAL
Intervention: Increased fresh gas flow from 40 to 120 ml.kg‐1 x min‐1 (Group 1)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Increased fresh gas flow and charcoal filter (Group 2)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Increased fresh gas flow and change of anaesthetic machine (Group 3)
Number of subjects: 45
Study: 3634793

Group type: EXPERIMENTAL
Intervention: Educational pelvic examination
Number of subjects: 213

Group type: COMPARATOR
Intervention: Traditional pelvic examination
Number of subjects: 213
Study: 30400971

Group type: EXPERIMENTAL
Intervention: Machine supported progressive resistance training (n = 10)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Usual care (n = 10)
Number of subjects: 20
Study: 28108224

Group type: EXPERIMENTAL
Intervention: Elcatonin monotherapy (20 units weekly)
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Minodronic acid hydrate monotherapy (1 mg daily)
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Combination therapy (elcatonin and minodronic acid hydrate)
Number of subjects: 51
Study: 26054049

Group type: EXPERIMENTAL
Intervention: 20% portion size reduction
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: 40% portion size reduction
Number of subjects: 33

Group type: COMPARATOR
Intervention: Control (no portion size reduction)
Number of subjects: 33
Study: 23212730

Group type: EXPERIMENTAL
Intervention: Loss-focused psychotherapy approaches
Number of subjects: 193
Study: 21188563

Group type: EXPERIMENTAL
Intervention: Glucocorticoids + rituximab
Number of subjects: 62

Group type: COMPARATOR
Intervention: Glucocorticoids
Number of subjects: 62
Study: 18054305

Group type: EXPERIMENTAL
Intervention: Controlled hypotension (average 30% reduction in systolic tension) during the first operative phase; n=23
Number of subjects: 51

Group type: COMPARATOR
Intervention: Normotension maintained during the entire procedure; n=28
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Controlled hypotension
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Controlled hypotension with nitroprusside
Number of subjects: 51
Study: 16825268

Group type: EXPERIMENTAL
Intervention: 10 g/day bovine colostrum protein concentrate (CPC)
Number of subjects: 29

Group type: COMPARATOR
Intervention: 10 g/day whey protein (placebo)
Number of subjects: 29
Study: 15126541

Group type: EXPERIMENTAL
Intervention: Growth Hormone (GH) treatment
Number of subjects: 37

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 37
Study: 11422471

Group type: EXPERIMENTAL
Intervention: BOAM (Colloidal bismuth subcitrate, omeprazole, amoxycillin, metronidazole)
Number of subjects: 34

Group type: COMPARATOR
Intervention: BAM (Colloidal bismuth subcitrate, amoxycillin, metronidazole)
Number of subjects: 34

Group type: COMPARATOR
Intervention: OAM (Omeprazole, amoxycillin, metronidazole)
Number of subjects: 34

Group type: COMPARATOR
Intervention: AM (Placebo bismuth, amoxycillin, metronidazole)
Number of subjects: 34
Study: 9471633

Group type: EXPERIMENTAL
Intervention: Affective psychoses and depressive neuroses
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Female patients suffering from depression or physical illness
Number of subjects: 0
Study: 8216665

Group type: EXPERIMENTAL
Intervention: Topical lignocaine 4 mg/kg (group A)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Rectal paracetamol 10 mg/kg (group B)
Number of subjects: 60

Group type: COMPARATOR
Intervention: No analgesia (group C)
Number of subjects: 60
Study: 3619708

Group type: EXPERIMENTAL
Intervention: Progabide
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 30145099

Group type: EXPERIMENTAL
Intervention: RV3-BB vaccine (neonatal schedule)
Number of subjects: 1649

Group type: EXPERIMENTAL
Intervention: RV3-BB vaccine (infant schedule)
Number of subjects: 1649

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1649
Study: 29906071

Group type: EXPERIMENTAL
Intervention: Cashew apple juice (240 mg/day)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Cashew apple juice (120 mg/day)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 45
Study: 25531294

Group type: EXPERIMENTAL
Intervention: Barbell deadlift training for 10 weeks
Number of subjects: 24

Group type: COMPARATOR
Intervention: Control group (no training)
Number of subjects: 24
Study: 22766450

Group type: EXPERIMENTAL
Intervention: Thermal Stimulation (TS)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control (3 consultations per week for 6 weeks)
Number of subjects: 30
Study: 21116892

Group type: EXPERIMENTAL
Intervention: MIS-BHA (Minimally Invasive Surgery - Bipolar Hemiarthroplasty)
Number of subjects: 83

Group type: COMPARATOR
Intervention: Conventional BHA
Number of subjects: 83
Study: 18928091

Group type: EXPERIMENTAL
Intervention: Chinese herbs for supplementing Shen, orally administered three days before and after ESWL
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group (usual diet and hydration)
Number of subjects: 60
Study: 15946284

Group type: EXPERIMENTAL
Intervention: Oral cryotherapy using ice cubes before and during chemotherapy infusions.
Number of subjects: 60
Study: 11677298

Group type: EXPERIMENTAL
Intervention: Tactile‐kinesthetic stimulation (structured baby massage)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Control group (no tactile‐kinesthetic stimulation)
Number of subjects: 48
Study: 9627740

Group type: EXPERIMENTAL
Intervention: d‐vitamin E (1600 IU per day)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study: 8154822

Group type: EXPERIMENTAL
Intervention: Acute perioperative normovolaemic haemodilution with retransfusion of autologous blood (900 ml taken preoperatively, replaced with 1000 ml of gelatin solution)
Number of subjects: 40

Group type: COMPARATOR
Intervention: No blood taken (control group)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Both groups allowed a fall in haematocrit (Hct) to 0.25 before transfusion started
Number of subjects: 40
Study: 2484360

Group type: EXPERIMENTAL
Intervention: Anti-oxidant cocktail (betacarotene, vitamins B6, C, E, zinc, selenium)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Anti-oxidant cocktail
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Vitamin B6 supplementation (2 mg daily)
Number of subjects: 45
Study: 29211857

Group type: EXPERIMENTAL
Intervention: Continued antiarrhythmic drug treatment (ADT ON)
Number of subjects: 153

Group type: COMPARATOR
Intervention: Discontinued antiarrhythmic drug treatment (ADT OFF)
Number of subjects: 153

Group type: EXPERIMENTAL
Intervention: Quality-of-life scores in ADT ON group
Number of subjects: 153

Group type: COMPARATOR
Intervention: Quality-of-life scores in ADT OFF group
Number of subjects: 153
Study: 28700482

Group type: EXPERIMENTAL
Intervention: Fu-Zheng-Qu-Zhuo oral liquid (FZQZ)
Number of subjects: 68

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 68
Study: 23816199

Group type: EXPERIMENTAL
Intervention: Aftercare services including treatment follow-up (home care or telephone follow-up), family psychoeducation, and patient social skills training provided by community mental health teams.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Treatment as usual (TAU)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Aftercare services
Number of subjects: 0
Study: 21714999

Group type: EXPERIMENTAL
Intervention: GAD‐alum (20 μg, three injections)
Number of subjects: 145

Group type: EXPERIMENTAL
Intervention: GAD‐alum plus alum (20 μg GAD‐alum, two injections and one of alum)
Number of subjects: 145

Group type: COMPARATOR
Intervention: Alum (three injections)
Number of subjects: 145

Group type: COMPARATOR
Intervention: GAD‐alum vs alum
Number of subjects: 145

Group type: COMPARATOR
Intervention: GAD‐alum plus alum vs alum
Number of subjects: 145

Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 145
Study: 19400340

Group type: EXPERIMENTAL
Intervention: Breathing training
Number of subjects: 0

Group type: COMPARATOR
Intervention: Asthma education (control)
Number of subjects: 0
Study: 16671517

Group type: EXPERIMENTAL
Intervention: Uvulopalatopharyngoplasty with uvula preservation
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Uvulopalatopharyngoplasty with uvula preservation and radiofrequency tongue base reduction
Number of subjects: 46

Group type: COMPARATOR
Intervention: Both groups (comparison)
Number of subjects: 46
Study: 15541202

Group type: EXPERIMENTAL
Intervention: Pain-eliciting transcutaneous electrical stimulation (TES)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Non-pain transcutaneous electrical stimulation (TES)
Number of subjects: 12
Study: 11385210

Group type: EXPERIMENTAL
Intervention: Heparinoid group
Number of subjects: 1219

Group type: EXPERIMENTAL
Intervention: Placebo group
Number of subjects: 1219

Group type: COMPARATOR
Intervention: PC patients
Number of subjects: 1219